IL5 and chronic rhinosinusitis with nasal polyps: Mepolizumab, as a subcutaneously administered anti–IL-5 therapy, is a precision-targeted systemic therapy directed against the underlying disease process in both CRSwNP and SA, with a favorable safety profile compared to OCS.35